Heyu Medicine, a leader in the development of new oncology drugs in China, successfully listed on the Hong Kong main board, Qiming Ventures welcomes its 10th IPO this year

Shanghai, October 15, 2021/PRNewswire/ - On October 13, Beijing time, Qiming Venture Capital, China's leading tumor drug research and development leader, and Yu Medicine successfully listed on the main board of the Hong Kong Stock Exchange

As an early investor, Qiming Venture Capital led the investment in Heyu Medicine's B round of financing in 2019, and continuously participated in the company's C and D rounds of investment.

The successful listing of Heyu Medicine is also Qiming Venture Capital's 10th IPO since the beginning of 2021

Founded in 2016, Heyu Medicine is a R&D-driven, clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and differentiated small molecule tumor therapies

With strong discovery capabilities, Heyu Medicine has strategically designed and developed 14 pipelines focused on oncology, of which 12 have global R&D and commercialization rights, and the other 2 are exclusively imported from AstraZeneca and X4 therapeutics Products

At present, Heyu Medicine has established a multi-dimensional discovery platform that can comprehensively conduct cancer genomics and screening, computational medicinal chemistry, transformation and biomarker science

Focusing on the needs of patients and the pharmaceutical market, and adhering to the concept and standards of international new drug development, along with the listing, Heyu Pharmaceutical will continue to develop novel and high-potential drug targets FIRST-IN-CLASS or BEST-IN-CLASS innovative drugs for Improve the quality of life of patients in China and around the world

Hu Xubo, partner in charge of Qiming Venture Capital, said: “As one of the early investors, Qiming Venture Capital has witnessed the growth of Heyu Medicine.

About Qiming Venture Capital

Qiming Venture Capital was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and San Francisco Bay Area

At present, Qiming Venture Capital manages nine US dollar funds and six RMB funds, with total assets under management of US$5.

Up to now, Qiming Ventures has invested in more than 400 fast-growing innovative companies, of which more than 150 are traded on the New York Stock Exchange, Nasdaq, Hong Kong Stock Exchange, Taiwan OTC, Shanghai Stock Exchange and Shenzhen Stock Exchange.

Among Qiming Venture Capital's investment companies, many have grown into the most influential companies in their respective fields, including Xiaomi Group (01810.

Source: Qiming Venture Capital